GIST Support International
Latest News
NIH Pediatric GIST Clinic

Z9000 Adjuvant Imatinib Trial

Sorafenib Is Promising

Latest Content Updates
GSI Community
GIST Support International: Gastrointestinal Stromal Tumor patient education and support
Monitoring Tests
Current Trials

Current Trials

Click a bulleted link below to jump to that section of trial listings.

  • Inhibitors of KIT, PDGFR and VEGF
  • HSP90 Inhibitors
  • Inhibitors of Targets Downstream of KIT & PDGFR
  • Drug Combination Trials
  • Other Trials

    Inhibitors of KIT, PDGFR and VEGF

    Trial Name (click for link)PhaseID & Status
    Study comparing 12 months versus 36 months of Imatinib in the treatment of Gastrointestinal stromal Tumor (GIST)IIINCT00116935
    recruiting
    The Biological Activity of AZD2171 in GISTIINCT00385203
    not recruiting
    Post-Marketing Clinical Study of Postoperative Adjuvant Therapy with Imatinib Mesylate Patients with Gastointestinal Stromal Tumors (GIST)IVNCT00171977
    not recruiting
    Prospective Multicentric Randomized Study of Glivec in Advanced Gastointestinal Stromal Tumors Expressing c-Kit: Interruption After 3 Years vs. MaintenanceIIINCT00367861
    recruiting
    Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorIINCT00112632
    recruiting
    Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST IINCT00500188
    recruiting
    Efficacy and safety of AMN107 Compared With Current Treatment Options in Patients with GIST Who Have Failed Both Imatinib and SunitinibIIINCT00471328
    recruiting
    Efficacy and safety of AMN107 (Nilotinib) Compared With Current Treatment Options in Patients with GIST Who Have Failed Both Imatinib and Sunitinib - ExtensionIIINCT00488150
    recruiting
    Imatinib Mesylate or Observation Only in Treating Patients Who have Undergone Surgery for Localized Gastointestinal Stromal TumorIII
    		NCT00103168
    recruiting
    Safety and Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal TumorsIIIb
    		NCT00372567
    recruiting
    Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal TumorIINCT00290485
    recruiting
    Post Marketing Surveillance Study To Observe Safety and Efficacy Of Sutent
    		NCT00444795
    admitting by invitation only
    Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate or Sunitinib MalateIINCT00265798
    recruiting
    A Continuation Study To Provide Sunitinib Malate For Patients Leaving Treatment on a Previous Sunitinib StudyIIINCT00428220
    recruiting
    Study of XL820 given Orally Daily to Subjects With Solid TumorsINCT00350831
    not recruiting
    A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or SunitinibIINCT00570635
    recruiting
    A Study of OSI-930 in Cancer PatientsINCT00513851
    recruiting
    MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or LymphomaINCT00504205
    recruiting
    Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinase (TK) InhibitorIINCT00633295
    not yet recruiting
    Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)IINCT00290485
    recruiting
    Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal TumorsIINCT00568750
    recruiting
    A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SUO11248IINCT00094029
    recruiting
    Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal TumorspilotNCT00580281
    recruiting

    HSP90 Inhibitors

    Trial Name (click for link)PhaseID & Status
    Safety Study of IPI-504 in Patients with Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)INCT00276302
    recruiting
    Study of Oral CNF2024 in Advanced Solid Tumors or LymphomasINCT00345189
    recruiting
    Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor MalignanciesINCT00506805
    recruiting
    Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer PatientsI-IINCT00526045
    recruiting
    An Open-Label 18FDG-PET Pharmocodynamic Assessment of the Effect of BIIB021 In Subjects With Gastrointestinal Stromal Tumors (GIST)IINCT00618319
    recruiting

    Inhibitors of Targets Downstream of KIT & PDGFR

    <><><><>
    Trial Name (click for link)PhaseID & Status
    Study of BEZ235 for Advanced Solid MalignanciesINVCI0635
    recruiting

    A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PIKinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors

    		Inot listed
    recruiting
    Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid TumorsINCT00486135
    recruiting
    Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid TumorsINCT00485719
    recruiting

    A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

    		I/IINCT00600275
    recruiting

    Drug Combination Trials

    Trial Name (click for link)PhaseID & Status
    Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal TumorsINCT00573404
    Recruiting
    INCT00121264
    Recruiting
    Phase II Study of Perifosine Plus Gleevec for Patients with GISTIINCT00455559
    recruiting
    Oblimersen and Imatinib Mesylate in Treating Patients with Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By SurgeryIINCT00091078
    not recruiting
    Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid TumorsINCT00098592
    recruiting
    Phase I Study of Imatinib Mesylate and SUO11248 (Sunitinib) for Patients with GISTINCT00495001
    recruiting
    Imatinib Mesylate With or Without Bevacizumab in Treating Patients with Metastatic or Unresectable Gastrointestinal Stromal TumorIIINCT00324987
    not yet recruiting
    Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateII-IIINCT00510354
    recruiting
    Phase II Study of Imatinib and Pegylated Interferon-a 2B In Imatinib-naive GIST PatientsIINCT00585221
    recruiting
    Patients Completing Core Protocol (CAMN107A2103).Exhibiting Stable Disease (SD), Partial Response (PR), or Complete Response (CR) to Nilotinib in Combination With ImatinibINCT00441155
    not recruiting

    Other Trials

    Trial Name (click for link)PhaseID & Status
    A Study of Oral PX-478 in Advanced Solid Tumors or LymphomaINCT00522652
    recruiting
    Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Imatinib Mesylate Refractory Advanced / Metastatic Malignant GISTIINCT00359333
    recruiting
    Doxyrubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot be Removed by SurgeryINCT00098579
    recruiting
    FR901228 in Treating Patients With Metastatic or Unresectable Soft Tissue SarcomaIINCT00112463
    not recruiting
    Radiation Therapy as Palliative Treatment of GIST (GIST-RT)I-IINCT00515931
    recruiting
    Rapamycin With Grapefruit Juice for Advanced MalignanciesINCT00375245
    recruiting



    • back to top
    Copyright © 2006 GIST Support International. Disclaimer We subscribe to the HONcode principles. HON CODE